IPNews® – The Federal Circuit ruled in favor of pharmaceutical giant Allergan, saying that two generic-drug manufacturers would infringe its patent if they attempted to make a generic form of Lumigan, a patented drug for glaucoma patients.

Barr Laboratories, Inc. and Sandoz, Inc. were found by the lower court to not have sufficiently proven their claims that Allergan’s patent was invalid due to prior art and obviousness.  The Federal Circuit upheld the decision and banned the companies from making a generic form of the drug until the patent expires.

To continue reading, click:  Allergan Wins Patent Infringement Suit Against Generic-Drug Manufacturers